Archive for: Drug Pricing

  • ORIGINAL ANALYSIS

  • PDF DOWNLOAD

  • EXTERNAL LINK

  • POST

Insight: original analysis

McDermottPlus Check-Up: April 12, 2019

This Week’s Dose: Drug pricing continues to be the focus in Congress with multiple hearings and markups on the subject. So far, lowering drug prices remains a rare area of consensus among lawmakers.

ORIGINAL ANALYSIS

Insight: original analysis

Analyzing the President’s FY 2020 Budget: Key HHS Proposals

On March 11, 2019, the White House released its FY 2020 budget proposal. In the area of health care, the president has requested $87.1 billion in discretionary budget authority for HHS, which represents a 12 percent decrease from the 2019 estimated level. Read on for key HHS proposal highlights.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: March 8, 2019

This Week’s Diagnosis: Hearings, hearings and more hearings. FDA Commissioner Scott Gottlieb is stepping down. Budget talks heat up.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: February 22, 2019

This Week’s Diagnosis: It’s all quiet on the Hill. Members return Monday after the first full week of district work time in the 116th Congress.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: February 15, 2019

This Week’s Diagnosis: Congress passed a $328 billion spending package to avert another government shutdown.  President Trump is expected to sign it.  Congressional hearings continue to focus on coverage and drug pricing.  

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: February 8, 2019

This Week’s Dose: The State of the Union briefly highlighted a few Administration health initiatives. The House continues its focus on the Affordable Care Act (ACA). The Senate is pressuring CEOs from the largest drug manufacturers to testify.  

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: February 1, 2019

This Week’s Diagnosis: Government reopens…for at least three weeks. Congress is full steam ahead, kicking off the 116th with health care hearings on drug pricing and pre-existing conditions. The US Department of Health and Human Services focuses on 2019 priorities.

ORIGINAL ANALYSIS

Insight: original analysis

McDermott Plus Check-up: January 25, 2019

This Week’s Diagnosis: Hearings are beginning and priorities are emerging. The shutdown drags on. And updates are trickling out of the Administration.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: January 11, 2019

This Week’s Diagnosis: Welcome back – sort of. The partial federal government shutdown drags on. We are on day 21 with no end in sight, which has shifted the focus of the new Congress away from overarching health priorities and toward continued efforts to reopen the government.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: December 7, 2018

This Week’s Diagnosis: Memorial services for President George H.W. Bush were held this week in Washington, DC and Texas. No agreement has been reached on border wall funding, which means Members may be here through at least December 21.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: November 30, 2018

This Week’s Diagnoses: Welcome back! Members are back in town for a sprint to the finish. Controversy over the House Democratic leadership elections fizzled, with the same faces in the top three positions.

ORIGINAL ANALYSIS

Insight: original analysis

Election Results Bring Change in Health Priorities

Democrats will take control of the House of Representatives in January 2019. Republicans will retain control of the Senate, widening their margin slightly. Split control of Congress will have important consequences for healthcare policy.  This article takes a closer look at how the election is likely to impact the health policy agenda.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: October 26, 2018

This Week’s Diagnosis: The Administration remains active with the issuance of several new guidance documents, the drug pricing announcement and the President (finally) signing the bipartisan opioid legislation (HR 6).

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: October 19, 2018

This Week’s Diagnoses: All eyes are on the midterm election, now less than three weeks away.  The House and Senate are out; the Administration continues to release health-related regulations and announcements.

ORIGINAL ANALYSIS

Insight: original analysis

McDermottPlus Check-Up: September 28, 2018

This Week’s Diagnosis: Consideration of the Kavanaugh nomination dominated airtime in the Senate this week, but the House stayed on-task, pushing through a number of health-related bills.

ORIGINAL ANALYSIS

Insight: original analysis

Oklahoma Is the Place to Be . . . Especially for Value-Based Contracting

This article—the latest in a McDermott+Consulting series investigating the president’s drug pricing plans—takes a closer look at Oklahoma’s recently approved State Plan Amendment that allows Oklahoma to negotiate value-based contracts with drug makers for individuals covered by the state’s Medicaid plan.

ORIGINAL ANALYSIS

Insight: original analysis

White House Builds Momentum for Drug Price Controls

On May 11, 2018, President Trump released the American Patients First Blueprint, a plan to lower drug prices and reduce beneficiary out-of-pocket spending on drugs in the Medicare program.

ORIGINAL ANALYSIS

Insight: original analysis

White House Swings for Fences with FY 2019 Drug Pricing Proposals

Since the run-up to the 2016 presidential election, Donald Trump has stated his interest in controlling and lowering the high cost of prescription drugs. Until recently his administration had released limited details on possible ways to do so.

ORIGINAL ANALYSIS

Load more
beakernav X1E2BFA62-BFCE-43C1-B777-27E3E5216018medical bagoriginal analysis +external linkpdf downloadstethoscope